Zydus Lifesciences Limited
Zydus Lifesciences Limited has informed the Exchange regarding a press release dated October 21, 2026, titled "Zylidac Bio and Prolific Machines Partner to Scale Prolific s Next-Generation Biologics Manufacturing Platform to GMP Production".
Filed with NSE · ISIN INE010B01027 ·
6ix is reading this filing.
View original source (NSE India)Zydus Lifesciences Limited on 6ix
Story so far
- Zydus Lifesciences Limited has informed the Exchange regarding a press release dated October 21, 2026, titled "Zydus receives USFDA approval for Estradiol and Levonorgestrel Transdermal System, eligible for 180-day CGT exclusivity".
- Zydus Lifesciences Limited has informed the Exchange regarding a press release dated October 15, 2026, titled "Zydus Sunshine Lifesciences signs agreement with Board of Investment, Sri Lanka to establish a pharmaceutical manufacturing facility in Sri Lanka".
- Zydus Lifesciences Limited has informed the Exchange regarding a press release dated October 13, 2026, titled "USFDA inspection concludes at Zydus' manufacturing plant at Moraiya, Ahmedabad".
Earlier from Zydus Lifesciences
- Zydus Lifesciences Limited has informed the Exchange regarding a press release dated October 21, 2026, titled "Zydus receives USFDA approval for Estradiol and Levonorgestrel Transdermal System, eligible for 180-day CGT exclusivity".
- Zydus Lifesciences Limited has informed the Exchange regarding a press release dated October 15, 2026, titled "Zydus Sunshine Lifesciences signs agreement with Board of Investment, Sri Lanka to establish a pharmaceutical manufacturing facility in Sri Lanka".
- Zydus Lifesciences Limited has informed the Exchange regarding a press release dated October 13, 2026, titled "USFDA inspection concludes at Zydus' manufacturing plant at Moraiya, Ahmedabad".
- Zydus Lifesciences Limited has informed the Exchange regarding a press release dated October 13, 2026, titled "Zydus and Formycon: FYB206 Becomes First Publicly Announced Keytruda® Biosimilar Accepted for Review by USFDA".
- Zydus Lifesciences Limited has informed the Exchange regarding a press release dated October 12, 2026, titled "Zydus Therapeutics Presents New Post Hoc Analysis of Phase 3 EPICS-III Trial at ACG 2026 Showing Greater Biochemical Response With Investigational Saroglitazar Compared to Placebo Across Geographic Subgroups in PBC".
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences